Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

TAK-279 effectively reduces psoriasis symptoms and is safe.

In this case report, a 64-year-old woman developed alopecia areata after starting the IL-17A inhibitor secukinumab for psoriasis, highlighting a potential rare side effect of this treatment, with only three similar cases reported in the literature.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This study found that dutasteride affected spinal bone formation in curdlan-treated SKG mice, while DHT treatment reduced osteoblast differentiation in vitro, suggesting that DHT inhibition might unexpectedly increase spinal ankylosis progression in ankylosing spondylitis patients.

In this study, researchers found that the protein eIF4E is crucial for keratinocyte proliferation in psoriasis, suggesting it as a potential treatment target for the condition.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.

This case control study investigated serum IL-17A levels in alopecia areata patients compared to healthy controls to explore its potential role in the disease's pathogenesis.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study observed that in aged mouse skin, there was an increase in IL-17-expressing T helper cells, γδ T cells, and innate lymphoid cells, and blocking IL-17 signaling reduced skin inflammation and delayed age-related changes, suggesting it as a potential target to mitigate skin aging.

In this study using mouse models, researchers found that elevated IL-17a in aged olfactory epithelium impairs olfactory function, while IL-17a inhibition promotes regeneration and mitigates age-related decline.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.

This study found that several synthesized pregnane derivatives exhibited significant inhibitory effects on testosterone conversion to dihydrotestosterone and reduced related androgenic parameters in multiple pharmacological models.

This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.